tbuckley/cabot-search huggingface dataset:
FRI0682 Follow-up of treatment response with dynamic doppler ultrasound in raynaud'sphenomenon
Authors: U Toprak, Z Ozbalkan, M Edugan, S Parlak, SC Sandıkci, T Kaya, S Saylisoy
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> This study aims to investigate the role of flow parameters obtained by dynamic Doppler ultrasound in the objective follow-up of treatment response in Raynaud9s phenomenon (RP) cases. <h3>Methods</h3> The study included newly diagnosed 33 patients with primary RP (PRP), 31 patients with secondary RP (SRP), and 26 healthy controls. The control group was evaluated with Doppler once, while the patients before treatment and on the third month of thet reatment. Baseline and post-cold provocation diameter (BD, CPD, mm) andflowvolume (BFV, CPFV, mL/min); post-coldprovocationflowstarting time (FST, min), and flowv olume normalizing time (FVNT, min) were recorded. Statistical analysis: for disturubution of thes ex of the groups: chi-square test, for analysing age distrubution among the groups One-way ANNOVA; for analysing the pre and post treatment doppler results: Wilcoxon test and fo rcomparison of the PRP and SRP post treatment values to control group; Krusal Wallis test were used. A p value less than 0,05 was considered statistically significant. <h3>Results</h3> Before-after treatment, there was no significant improvement in the BD in both PRP and SRP groups (0.79±0.17–0.82±0.19 vs. 0.66±0.13–0.68±0.14 PRP vs. SRP, respectively), while FST did not significantly improve in the PRP group (1.15±2.27–0.61±1.41 vs 3.13±4.81–1.58±2.36) (p&gt;0.05). A significant improvement was observed in baseline flow volüme (3.08±2,96 vs 3.91±3.39 (p: 0,002),flow volume normalization time (7.24±7.60 vs 3.84±3.39) (p: 0,0001), after cold provocation flow volume (1.18±1,26 vs 2.17±2.16) (p: 0,0001), after cold provocated diameter (0.63±0.15 vs 0.70±0.16) (p: 0,005) in PRP group after treatment. In SRP group, only baselined iameter changes were not influenced by the treatment, all other post treatmen tparameters were impoved in all SRP cases including baseline flow volume (2.14±1.94 vs 2.80±2.15) (p:0,009), after cold provocation diameter (0.56±0.15 vs 0.63±0.13) (p: 0.004), after cold provocation flow volume (1.07±1.40 vs 1.46±1.67) (p: 0,004), flow starting time (3.13±4.81 vs 1.58±2.36) (p: 0,021) and flow volume normalisation time (9.58±8.49 vs 4.32±3.56) (p: 0,0001). There was an improvement in parameters after the treatment in both RP groups comparing by the control groups (p&lt;0.01). <h3>Conclusions</h3> Doppler ultrasound is an objective, cost-effective, safe (does not include radiation), and easy-to-use method in thefollow-up of RP patients on macrovascular level with or without cold provocation before and after treatment. <h3>Acknowledgements</h3> Keywords: Raynoud Phenomenon, treatment, Doppler ultrasound <h3>Disclosure of Interest</h3> None declared
FRI0667 The recall survey: can ultrasound affects clinicians' decisions about changing treatment in ra?
Authors: O Epis, P Macchioni, A Delle Sedie, M Canzoni, E Filippucci, A Iagnocco, S Tropea, CF Bonali
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In Rheumatoid Arthritis (RA) treatment response is assessed using standard clinical disease activity measure. However ultrasound (US) is able to show subclinical synovitis in patients (pts) with RA who are in clinical remission (CR); further studies are still required to delineate the impact of US findings in the management of RA pts in daily clinical practice. <h3>Objectives</h3> to investigate the influence of US on the clinicians9 treatment choices in pts with RA. <h3>Methods</h3> in 2015 an educational event (RECALL Survey) focused on the added value of US in RA pts was held in 22 rheumatology centers in Italy.In every center, the local rheumatologists provided RA pts to be examined by US. Pts signed an informed consent and a brief history of them was collected by the local rheumatologists (previous and current therapy, DAS28, HAQ score). Bilateral US examinations of wrists, metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints were performed by rheumatologists expert in US, to assess synovitis (joint effusion, synovial proliferation, and power Doppler (PD) signal), and bone erosions, using a Logiq E R7, General Electrics, with a 4.2–13 MHz linear probe. All US findings were scored using a 4 degree semiquantitative scoring system. <h3>Results</h3> 465 pts were evaluated. Clinicians, after US evaluations, changed therapy in 23.7% of pts, did not change therapy in 35.5% of pts.In general changes of therapy tended to be made by clinicians when joint effusion or power Doppler signal were present (table 1–2). The presence of erosion did not influence the clinicians9 decisions. <h3>Conclusions</h3> Ultrasound may be an useful tool in daily rheumatologic practice to help clinicians make decisions about how to treat patients with RA. US results, especially joint effusion and Power Doppler signal, may influence the choice of clinicians to modify a patient9s treatment regime. <h3>Disclosure of Interest</h3> None declared
AB0308 Disease activity, grip strengths and hand dexterity in patients with rheumatoid arthritis
Authors: D Palamar, G Er, R Terlemez, U Isil, G Can, M Saridogan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting hand joints, and leading impairment in hand functions. To date many scientific studies assessed the disease activity of patients with RA, but little attention has been carried out to assess hand functions, and dexterity (1–2). <h3>Objectives</h3> The purpose of this study was to determine the clinical relevance of the Quick Disabilities of Arm, Shoulder and Hand (QuickDASH), hand dexterity with the Purdue Pegboard Test (PPT), and grip and pinch strengths of RA patients. <h3>Methods</h3> Eighty-two women with a diagnosis of RA according to the 2010 American College of Rheumatology/the European League Against Rheumatism (ACR/EULAR) criterion were recruited to the study. The disease activity scores were determined by using Disease activity score-28 (DAS-28). Grip strengths was measured with a Jamar dynamometer, and pinch strengths were measured by pinchmeter. Hand functions were evaluated with the PPT, and functional outcomes were assessed with the QuickDASH questionnaire. <h3>Results</h3> The mean age of the study group was 49.27±10.69 years. Average values of DAS-28, the QuickDASH values were found to be 4.22±1.28, 38.33±19.78, consecutively. High correlation was observed between DAS-28 and the QuickDASH values (p&lt;0.001). The mean grip strengths were significantly correlated with the QuickDASH and DAS-28 values (p&lt;0.01) (Table 1). The mean lateral pinch strengths were correlated significantly with DAS-28 and the QuickDASH scores (p&lt;0.001). DAS-28 was correlated with PPT performance just on the dominant hand (p&lt;0.05). The QuickDASH values were not correlated with all PPT performances (p&gt;0.05). Grip strengths were positively correlated with the PPT performances (p&lt;0.05). <h3>Conclusions</h3> In conclusion, we determined that grip strengths were significantly related to disability and disease activity in RA patients in our study. The clinical significance of QuickDASH is high, and the questionnaire can be used effectively. <h3>References</h3> Aktekin LA, Eser F, Baskan BM, et al. Disability of Arm Shoulder and Hand Questionnaire in rheumatoid arthritis patients: relationship with disease activity, HAQ, SF-36. Rheumatol Int.2011;31:823–6. Singh H, Kumar S, Talapatra P, et al. Assessment of hand functions in rheumatoid arthritis using SF-SACRAH (short form score for the assessment and quantification of chronic rheumatoid affections of the hands) and its correlation to disease activity. Rheumatol Int. 2012;32:3413–9. <h3>Disclosure of Interest</h3> None declared
Abstract 15252: Segmental Myocardial Perfusion Improves after Repeated Intramyocardial Cell Injection
Authors: Imke Mann, Sander F Rodrigo, Jan van Ramshorst, Saskia L Beeres, Jaap J Zwaginga, Imad Al Younis, Jeroen J Bax, Wim E Fibbe, Martin Schalij, Douwe E Atsma
Journal: Circulation (2014)

Introduction: We previously demonstrated that intramyocardial bone marrow mononuclear cell (MNC) injection improves segmental myocardial perfusion. This study was designed to evaluate in patients with recurrent refractory angina the effect of repeated injection on segmental myocardial perfusion. Methods: Twenty-one patients with recurrent refractory angina pectoris, who received 100x10^6 autologous MNC intramyocardially using the NOGA-system for a second time, were enrolled. Single-photon emission computed tomography was performed at baseline and 3 months after both injection procedures. The myocardium was divided into 17 segments and in both stress and rest images, segmental tracer activity was categorized on a 4-point scale. (1=&gt;75%; 2=50%-74%; 3=25%-49%; 4=&lt;25%) Segments demonstrating increased perfusion of at least 1 point in stress or rest perfusion were categorized as improved. Results: The second injection procedure was 4.6 ± 2.5 years after the first. In total, 139 segments were injected for the first time during either of the procedures, of which 80(58%) segments improved. Repeated injection in the same segment was performed in 45 segments. Of these segments, 18(40%) improved, less than after a first injection (P=0.030). Repeatedly injected segments can be subdivided in 29 previously responding segments (improved after the first injection) and 16 previously non-responding segments (not improved after the first injection). Of the responding segments, 13(45%) segments improved after repeated injection and of the non-responding segments, 5(31%) segments improved. This difference was not significant (P=.476). Conclusions: Segmental myocardial perfusion can improve after repeated intramyocardial MNC injection independently of the effect of the first injection, but the first injection is more effective.
Annals Story Slam - Going Gentle
Authors: Kevin Venus
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Story Slam - Going GentleFREEKevin Venus, MDKevin Venus, MDFrom University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0051 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Going Gentle "Going Gentle," by Dr. Kevin Venus (Duration 05:25)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Toronto, Toronto, Ontario, Canada.Current Author Address: Kevin Venus, MD, University of Toronto, Toronto, Ontario, Canada; e-mail, kevin.[email protected]ca. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: SS1 ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Electroporation of Dicer-Substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms' Tumor 1 (WT1)-Specific TCR-Redirected Cytotoxic T Cells
Authors: Diana Campillo-Davo, Fumihiro Fujiki, Johan M.J. Van den Bergh, Evelien L. Smits, Haruo Sugiyama, Viggo F.I. Van Tendeloo, Zwi N. Berneman
Journal: Blood (2016)
Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.
Authors: Hironori Ishigami, Yoshiyuki Fujiwara, Ryoji Fukushima, Atsushi Nashimoto, Hiroshi Yabusaki, Haruhiko Imamoto, Motohiro Imano, Yasuhiro Kodera, Yoshikazu Uenosono, Kenji Amagai, Shigenori Kadowaki, Hiroto Miwa, Takuhiro Yamaguchi, Hironori Yamaguchi, Toshiaki Watanabe, Joji Kitayama
Journal: Journal of Clinical Oncology (2016)

4014 Background: Intraperitoneal (IP) paclitaxel (PTX) provides sustained high local concentrations, and its efficacy has been shown in ovarian cancer. We developed a regimen combining IP PTX with S-1/PTX for the treatment of gastric cancer patients, and obtained promising results with a one-year overall survival (OS) rate of 78% in a phase II study. This multicenter phase III study evaluated the efficacy of IP PTX plus S-1/PTX compared to standard systemic chemotherapy. Methods: Eligibility criteria included pathologically confirmed gastric adenocarcinoma, peritoneal metastasis, and no or short-term (< 2 months) prior chemotherapy. Patients were randomized 2:1 to an IP (IP PTX plus S-1/PTX; IP PTX 20 mg/m2, intravenous [IV] PTX 50 mg/m2 on days 1 and 8, and S-1 80 mg/m2/day on days 1-14, q3 weeks) arm or a SP (S-1/cisplatin; IV cisplatin 60 mg/m2 on day 8, and S-1 80 mg/m2/day on days 1-21, q5 weeks) arm. Randomization was stratified by center, having received prior chemotherapy, and the extent of peritoneal disease. The primary endpoint was OS. Secondary endpoints were response rate and safety. Results: Between October 2011 and November 2013, 183 patients were enrolled, and 164 patients were included in the efficacy analysis. Baseline patient characteristics were balanced between the two arms except for ascites. Of 45 patients with massive ascites (beyond the pelvic cavity), 38 (84%) were randomized to the IP arm and 7 (16%) to the SP arm. The median OS for IP and SP were 17.7 and 15.2 months, respectively (stratified log-rank test, p = 0.080; hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.49-1.04, p = 0.081). For a sensitivity analysis using a stratified Cox regression model, adjusting for the baseline ascites, the HR was 0.59 (95%CI 0.39-0.87, p = 0.0079). The overall response rate was 53% in the IP arm, and 60% in the SP arm (p = 1.0). Both regimens were tolerable, and there were no treatment-related deaths. Conclusions: The primary analysis did not show the statistical superiority of the IP regimen. The sensitivity analysis, considering the imbalance of ascites, suggested clinical efficacy of IP PTX in gastric cancer with peritoneal metastasis. Clinical trial information: UMIN000005930.
AB0651 The effect of cyclophosphamide on pulmonary function and dependence on disease activity of interstitial lung disease associated with systemic sclerosis
Authors: M Vonk, W van den Hombergh, H Knaapen, S Simons, J Fransen, F van den Hoogen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The pathogenesis of interstitial lung disease associated with systemic sclerosis (SSc-ILD) is not completely elucidated, although it is believed that chronic alveolar inflammation leads to increasing fibrosis. Treatment strategies using cyclophosphamide (CYC) have been focusing on the inflammatory pathway of SSc-ILD. We hypothesized that CYC is more effective in patients that are in the early, inflammatory phase. <h3>Objectives</h3> The objectives of this study are to analyze the effects of intravenously CYC pulses (750mg/m<sup>2</sup>) on pulmonary function (FVC, DLCO) in SSc-ILD after 12, 24 and 36 months, and whether this effect is dependent on the extent of ILD, the proportion of ground glass compared to fibrosis, SSc disease duration or baseline DLCO &lt;60%. <h3>Methods</h3> Patients with SSc-ILD receiving CYC pulses between 2003 and 2015 were classified by the Goh (2008) criteria in either limited or extensive ILD, using HRCT at baseline independently judged by two raters. Pulmonary function tests were performed at 0, 6, 12, 24 and 36 months. Missing outcome data due to drop-out were replaced by last observation carried forward, except in case of death. <h3>Results</h3> Seventy-five patients were included, 33 with limited ILD, 42 with extensive ILD. There were no baseline differences in age, gender, SSc subtype classification, disease duration or autoantibody status. Mean FVC and DLCO were stable after 12, 24 and 36 months of follow-up (figure 1). There was no effect in the degree of change in mean FVC and DLCO for the different effect modifiers (table 2): the extent of ILD, proportion of ground glass compared to fibrosis, short SSc disease duration or baseline DLCO &lt;60%. <h3>Conclusions</h3> Mean FVC and DLCO in SSc-related ILD was stable during 36 months of follow-up after cyclophosphamide pulse therapy. The extent of ILD, proportion of ground glass, SSc disease duration and baseline DLCO &lt;60% did not influence the effect of CYC on pulmonary function. CYC did not appeare to be more effective in the early phase of SSc-ILD. <h3>Disclosure of Interest</h3> None declared
AB0834 Risk factors for decreased bone mineral density in inflammatory bowel disease in a tunisian cohorte
Authors: H Romdhane, M Cheikh, K Abdelghani, R Ennaifer, N Bel Hadj, A Laatar
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with inflammatory bowel disease [IBD] are at risk for metabolic bone disease. Many studies have identified various risk factors but most of them have involved western patients. <h3>Objectives</h3> The aim of this study was to investigate the prevalence and the risk factors for metabolic bone disease in Tunisian IBD patients. <h3>Methods</h3> Retrospective study including patients with IBD admitted in our department between January 2011 and December 2015. Demographic and clinical characteristics of patients were analysed. Bone mineral density of the femoral neck, total femur and lumbar spine was quantified by dual-energy X-ray absorptiometry. <h3>Results</h3> Among 82 patients followed for IBD (70.7% with Crohn9s disease; 29.3% with Ulcerative colitis), a bone densitometry was performed in 56% of cases (n=46). 16 patients have osteopenia and 7 had osteoporosis, as assessed by T-score. Univariate analysis showed that Crohn9n disease in particular ileal disease, high steroid dose and the presence of extra-intestinal manifestations were significantly associated with a low bone mineral density (for all p&lt;0.05). In the other hand, IBD duration since diagnosis, sexe, tabagism were not associated with bone loss. In multivariate regression analysis, risk factors for decreased bone mineral density were IBD duration since diagnosis, high steroid dose, ileal crohn9s disease and extra-intestinal manifestations. <h3>Conclusions</h3> In our Tunisian cohort of IBD patients, Crohn9s disease, high steroid dose and extra-intestinal manifestations were associated with increased risk for metabolic bone disease. High risk patients should be identified and appropriate therapies should be started early to improve long term quality of life. <h3>Disclosure of Interest</h3> None declared
Treatment with vemurafenib in patients with metastatic melanoma.
Authors: Janja Ocvirk, Marko Boc, Tanja Mesti, Martina Rebersek
Journal: Journal of Clinical Oncology (2016)

e21028 Background: This is an analysis of patients (pts) with metastatic melanoma (mM) designed to evaluate the efficacy and safety of vemurafenib in routine clinical practice. Methods: Baseline characteristics, vemurafenib-related adverse events, and efficacy data were collected from 65 mm pts who were treated with vemurafenib. Results: From April 2013 till December 2015, 129 pts were diagnosed with mm and in 71 pts (55%) tumor tissue was positive for BRAF V600E/K mutation (87% BRAF V600E and 13% BRAF V600K). 65 BRAF-positive pts were treated with vemurafenib therapy (median age 54, males 68%). Vemurafenib was given as first, second or third line treatment to 56 (86%), 6 (9%) and 3 (5%) pts respectively. Distribution by dissemination site was 74% M1c, 14% M1a and 12% M1b. Overall response rate (ORR) was 46%, and disease control rate (DCR) was 73%. Complete response (CR) was reported in 5 pts (9%), partial response (PR) in 20 pts (37%) and stable disease (SD) in 15 pts (27%). Median progression-free survival (PFS) was 6.4 months (95% CI, 4.9-7.9). At the time of analysis 9 pts are still on vemurafenib treatment. Median overall survival (OS) was 7.2 months (95% CI, 5.4-9.0) with 22 (41%) pts alive at the time of data analysis. OS for subgroup of patients with BRAF V600E mutation was 6.8 months (95% CI, 4.8-8.8) and BRAF V600K was 10.1 months (95% CI, 6.7-13.5). Both PFS and OS were shorter in patients with increased lactate dehydrogenase concentration at baseline: normal serum LDH – median PFS was 7.8 months (95% CI, 4.7-10.9), medians OS was 10.1 months (95% CI, 6.6-13.6); elevated serum LDH – median PFS was 4.8 months (95% CI, 3.9-5.7), medians OS was 5.7 months (95% CI, 4.1-7.3). Adverse events (AEs) were reported in 85% of pts. 83% of reported AEs were grade 1-2. The most frequent grade 3-4 AEs were rash (19%), fatigue (3%), SCC (3%), liver injury (3%), arthralgia (2%), myalgia (2%), oedema (2%) and anemia (2%). Conclusions: In line with results from randomized clinical studies vemurafenib demonstrated better outcomes in mm patients with BRAF V600K mutation and normal serum LDH concentration also in routine clinical practice.
Stretching the evidence behind tennis elbow: mobile app user guide
Authors: Luke J Heales, Michele Lastella, Brooke K Coombes, Bill Vicenzino
Journal: British Journal of Sports Medicine (2017)

Tennis Elbow.

Health and fitness.

iOS V.6.0 or later; Android V.2.3 or later.

iPhone $A5.99; Android $A5.99.

Tennis elbow (TE), formally known as lateral epicondylalgia, is a musculoskeletal condition associated with pain over the lateral elbow and histological changes of the common extensor tendon.1 Numerous treatments are advocated for this condition, with recent developments in the use of mobile technology now added to the list.

The application titled ‘Tennis Elbow’ is one of the few user-friendly applications incorporating education, a stretching programme, and a diary for recording symptoms and exercises undertaken. The rationale provided for the aetiology of TE is muscle shortening from overuse, and ‘The magic formula is now called stretch the flexors!’ (figure 1). The application recommends five stretching exercises, targeting muscles of the trunk and upper limb (eg, finger flexors, wrist extensors). It allows users to track the number of exercises performed and their pain intensity using a user-friendly, colour-coded rating …